Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.

@article{Durgam2016EfficacyAS,
  title={Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.},
  author={Suresh Durgam and Willie R Earley and Hua Guo and Dayong Li and G. N{\'e}meth and Istv{\'a}n Laszlovszky and Maurizio Fava and Stuart A. Montgomery},
  journal={The Journal of clinical psychiatry},
  year={2016},
  volume={77 3},
  pages={371-8}
}
BACKGROUND Cariprazine is an atypical antipsychotic currently under investigation as adjunctive therapy in patients with major depressive disorder (MDD) who have inadequate response to standard antidepressant therapy. METHOD A randomized, double-blind, placebo-controlled, flexible-dose study was conducted from December 2011 to December 2013 in adults who… CONTINUE READING